171 related articles for article (PubMed ID: 35667043)
1. Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?
D'Arena G; Sgambato A; Volpe S; Coppola G; Amodeo R; Tirino V; D'Auria F; Statuto T; Valvano L; Pietrantuono G; Deaglio S; Efremov D; Laurenti L; Aiello A
Hematol Oncol; 2022 Dec; 40(5):835-842. PubMed ID: 35667043
[TBL] [Abstract][Full Text] [Related]
2. The role of minimal residual disease in chronic lymphocytic leukemia.
Al-Sawaf O; Hallek M; Fischer K
Clin Adv Hematol Oncol; 2022 Feb; 20(2):97-103. PubMed ID: 35120090
[TBL] [Abstract][Full Text] [Related]
3. Optimization and Validation of an 8-Color Single-Tube Assay for the Sensitive Detection of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia Detected via Flow Cytometry.
Dowling AK; Liptrot SD; O'Brien D; Vandenberghe E
Lab Med; 2016 May; 47(2):103-11. PubMed ID: 27069028
[TBL] [Abstract][Full Text] [Related]
4. Performance of a novel eight-color flow cytometry panel for measurable residual disease assessment of chronic lymphocytic leukemia.
Chen X; Chen X; Zhao S; Shi Y; Zhang N; Guo Z; Qiao C; Jin H; Zhu L; Zhu H; Li J; Wu Y
Cytometry B Clin Cytom; 2024 May; 106(3):181-191. PubMed ID: 38535092
[TBL] [Abstract][Full Text] [Related]
5. Minimal/Measurable Disease Analysis in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma by Flow Cytometry.
Gao Q; Roshal M
Curr Protoc; 2022 Aug; 2(8):e503. PubMed ID: 35980134
[TBL] [Abstract][Full Text] [Related]
6. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
Rios-Olais FA; Hilal T
Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease in the treatment of chronic lymphocytic leukemia.
Uchiyama T; Yokoyama A; Aoki S
J Clin Exp Hematop; 2020 Dec; 60(4):138-145. PubMed ID: 33148932
[TBL] [Abstract][Full Text] [Related]
8. Assessing minimal residual disease in chronic lymphocytic leukemia.
Rawstron AC; Hillmen P
Curr Hematol Malig Rep; 2008 Jan; 3(1):47-53. PubMed ID: 20425446
[TBL] [Abstract][Full Text] [Related]
9. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice.
Stehlíková O; Chovancová J; Tichý B; Krejčí M; Brychtová Y; Panovská A; Francová Skuhrová H; Burčková K; Borský M; Loja T; Mayer J; Pospíšilová S; Doubek M
Int J Lab Hematol; 2014 Apr; 36(2):165-71. PubMed ID: 24028768
[TBL] [Abstract][Full Text] [Related]
10. Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
Nguyen PC; Nguyen V; Baldwin K; Kankanige Y; Blombery P; Came N; Westerman DA
Br J Haematol; 2023 Aug; 202(4):760-770. PubMed ID: 37052611
[TBL] [Abstract][Full Text] [Related]
11. [Minimal residual disease in chronic lymphocytic leukemia: A still current issue in 2018].
Gauthier M; Comont T; Vergez F; Ysebaert L
Bull Cancer; 2018 Nov; 105(11):1042-1051. PubMed ID: 30243477
[TBL] [Abstract][Full Text] [Related]
12. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
13. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
Thompson M; Brander D; Nabhan C; Mato A
JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
[TBL] [Abstract][Full Text] [Related]
14. Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients.
Brett VE; Dilhuydy MS; Lechevalier N; Adjibabi AN; Gros FX; Forcade É; Letestu R; Vial JP
Ann Biol Clin (Paris); 2023 Oct; 81(4):379-387. PubMed ID: 37864443
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.
Moreno C; Villamor N; Colomer D; Esteve J; Giné E; Muntañola A; Campo E; Bosch F; Montserrat E
Blood; 2006 Jun; 107(11):4563-9. PubMed ID: 16449533
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
17. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia.
Rawstron AC; Villamor N; Ritgen M; Böttcher S; Ghia P; Zehnder JL; Lozanski G; Colomer D; Moreno C; Geuna M; Evans PA; Natkunam Y; Coutre SE; Avery ED; Rassenti LZ; Kipps TJ; Caligaris-Cappio F; Kneba M; Byrd JC; Hallek MJ; Montserrat E; Hillmen P
Leukemia; 2007 May; 21(5):956-64. PubMed ID: 17361231
[TBL] [Abstract][Full Text] [Related]
18. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R; Dahmani A; Boubaya M; Baseggio L; Campos L; Chatelain B; Debliquis A; Drénou B; Jacob MC; Legac E; Le Garff-Tavernier M; Lhoumeau AC; Quiney C; Robillard N; Ticchioni M; Aanei C; Katsahian S; Delepine R; Vaudaux S; Rouillé V; Béné MC; Dartigeas C; Van Den Neste E; Leprêtre S; Feugier P; Cartron G; Leblond V; Lévy V; Cymbalista F;
Leukemia; 2021 Jun; 35(6):1597-1609. PubMed ID: 32934355
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA; García Marco JA
Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
